Clinical Trials Browser

NCT05922930 2026-02-19

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Phase 1/2 Recruiting

51 enrolled

GastrointestinalGynecologic

Adenocarcinoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06782932 2025-12-03

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Phase 1/2 Recruiting

38 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT01088789 2025-08-26

Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

Phase 2 Active not recruiting

71 enrolled 13 charts

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT03153410 2025-01-09

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Phase EARLY_PHASE1 Completed

11 enrolled 14 charts

Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT06532799 2024-11-12

BAH250

Phase 1/2 Recruiting

75 enrolled

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03215810 2023-07-24

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Phase 1 Completed

20 enrolled 10 charts

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Recurrence, Carcinoma, Adenosquamous

NCT00887536 2022-04-20

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Phase 3 Completed

1,613 enrolled

Breast

Adenocarcinoma, Breast Diseases, Breast Neoplasms, Carcinoma

NCT02234921 2018-10-11

DRibble

Phase 1 Completed

3 enrolled

Adenocarcinoma, Neoplasm Metastasis, Sialorrhea

NCT00140075 2011-05-26

Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

Phase 3 Completed

606 enrolled

Tumor-Agnostic

Adenocarcinoma